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ABSTRACT
miRNAs are nodal regulators of gene expression
and deregulation of miRNAs is causally associated
with different diseases, including cancer. Modulation
of miRNA expression is thus of therapeutic impor-
tance. Small molecules are currently being explored
for their potential to downregulate miRNAs. Peptides
have shown to have better potency and selectivity to-
ward their targets but their potential in targeting and
modulating miRNAs remain unexplored. Herein, us-
ing phage display we found a very selective peptide
against pre-miR-21. Interestingly, the peptide has the
potential to downregulate miR-21, by binding to pre-
miR-21 and hindering Dicer processing. It is selective
towards miR-21 inside the cell. By antagonising miR-
21 function, the peptide is able to increase the ex-
pression of its target proteins and thereby increase
apoptosis and suppress cell proliferation, invasion
and migration. This peptide can further be explored
for its anti-cancer activity in vivo and may be even
extended to clinical studies.
INTRODUCTION
MicroRNAs are small noncoding RNAs, playing crucial
roles in regulating cellular function via post transcriptional
gene regulation (1). They are transcribed to form a long
precursormiRNA(pri-miRNA)which gets processed inside
nucleus by microprocessor complex to form stem loop in-
termediate of around 70 nt long (pre-miRNA) which then
get exported to cytoplasm via exportin and again gets pro-
cessed to form a mature miRNA duplex. Mostly, the strand
with relatively less thermodynamic stability in the duplex,
the guide strand (mature miRNA) gets incorporated to
RISC complex and binds to 3′ UTR of its target and causes
translational suppression and/or mRNA decay (2).
miRNAs control as much as 60% of all human genes (3)
and play a pivotal role in different cellular processes, includ-
ing development, stress response, cell proliferation, apop-
tosis, immunity, hematopoiesis and induction and main-
tenance of pluripotency (4–7). Dysregulated miRNA ex-
pression has been causally associated with different dis-
ease pathologies, including cancer, diabetes, cardiovascu-
lar disease, neurological disorder etc (8–10). In case of
cancer, around 40% of miRNAs are overexpressed (11,12)
and are shown to be involved in cancer initiation, pro-
gression, metastasis and resistance to therapeutic drugs
(13). Thus, modulation of miRNA expression is of thera-
peutic importance. The well-known miRNA inhibitors are
oligonucleotide based antisense oligonucleotide (anti-miR),
sponges and DNAzyme (14–16). Though they are ideal
tools for deciphering the role of a specific miRNA in dis-
ease context, their suboptimal delivery, low scalability, un-
favorable pharmacodynamic and pharmacokinetic proper-
ties are some of the major hurdles in their therapeutic ap-
plication (17). This paves the way for exploring alternative
strategies for miRNA modulation. Very recently, different
groups, including us, have shown promising impact of small
molecules in modulating miRNA expression and its func-
tion (18–31). Though this small molecule mediated modu-
lation of miRNA is a potentially important area to explore,
adequate selectivity is difficult to attain. Small molecule in-
hibitors against a particular miRNA have been termed as
selective by checking its effect only on a very small subset of
miRNAs.MiRnome-wide effect of these miRNA inhibitors
have to be explored and parallel efforts have to be made to
look for a class of miRNA inhibitors that are intrinsically
farmore selective. Last decade has seen enormous growth in
peptide based drugs because of their exquisite potency and
selectivity toward their molecular targets. Peptides are very
well reported to selectively bind to RNA (32). This gave us a
clue to look for selective peptide inhibitors against miRNA.
miR-21 is one of the most well studied miRNA, which is
consistently upregulated in different types of cancer. Con-
ditional over expression and inactivation of miR-21 was di-
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rectly correlated with tumor formation and regression in
mice model, showing its oncogenic potential (33). miR-21 is
known to play major role in cancer progression by favoring
cancer cell invasion, migration and proliferation, metastasis
and also by preventing apoptosis (34–36). Thus, miR-21 is
a strong candidate miRNA to target in case of cancer and
downregulation of miR-21 and modulation of its function
is of promising therapeutic importance.
Recently, phage display technology has allowed us to find
selective peptide(s) against RNA of interest by screening a
peptide library of around 109 or more complexity (37,38).
We have used phage display against pre-miR-21 to find out
a selective peptide that binds to pre-miR-21 and blockDicer
processing and thereby downregulate miR-21 expression.
This peptide is very selective to miR-21 inside cell. We have
also shown that the peptide inhibitor increases apoptosis,
suppress cell invasion and migration.
MATERIALS AND METHODS
In vitro transcription of pre-miR-21
The pre-miR-21 RNA was in vitro transcribed as described
previously (18). This was further gel purified using 15% de-
naturing polyacrylamide gel electrophoresis (PAGE).
Biotinylation of pre-miR-21
The PAGE purified pre-miR-21 was biotinylated using
Thermo Scientific Pierce RNA 3′ End Biotinylation Kit us-
ing manufactures protocol.
Phage display selection against pre-miR-21
We have used Ph.D.-12 library for the selection where 12
mer random peptide was fused to the N-terminus of mi-
nor coat protein pIII of M13 phage. The library has around
109 complexity. Phage display selection was carried out as
described previously (37). The entire panning was done
at room temperature. For the initial negative selections,
25 l of magnetic Dynabeads (M-280 streptavidin beads)
were washed three times with 100 l Solution A (0.1 M
NaOH, 0.05 M NaCl), once with 100 l of buffer B (0.1
M NaCl) and then once with RNA/phage washing buffer
(10 mM Tris·HCl, pH 7.5, 10 mM MgCl2, 150 mM NaCl,
1 mM DTT). During each washing, the tubes were set on
a magnetic holder while the supernatant was removed. 10
l phage library (∼ 1012 pfu) was added to the beads, in-
cubated for 30 min, and supernatant was removed. The
bead bound phages were eluted as described in the protocol
for the Ph.D.-12 library and titered. This negative selection
was carried out to remove the streptavidin and tube bind-
ing phages. After four rounds of consecutive negative selec-
tions (supernatant was passed directly to the next round),
we found no bead binders (there was no eluted phage while
titrating for the bead binders, after fourth round of negative
selection), suggesting that the final pool was devoid of any
streptavidin or plate binder. Positive selection for binding to
pre-miR-21 was carried out using this final depleted pool.
Fifty pmoles (or 30 pmoles in third and fourth rounds) of bi-
otinylated pre-miR-21 were added to pre-washed beads and
incubated for 30 min at RT. Pre-miR-21 bound tubes were
washed with RNA/phage binding buffer A, pre-screened
phage library was added to it and incubated at room tem-
perature for 30 min. Tubes were washed with 200 l of
RNA/phage washing buffer containing 0.1% Tween-20.
Bound phages were eluted by glycine (0.2 M glycine, pH
2.2). The eluted phage pool was amplified in Escherichia
coliER2738 and the procedure was repeated for subsequent
rounds, without additional pre-screening. The stringency of
washing was increased, by increasing the number of washes
and amount of Tween-20, in consecutive rounds. To in-
crease the selectivity against pre-miR-21, the phages were
pre-incubated with non-biotinylated pre-miR-27a and total
RNA from HEK cell line (where miR-21 expression level is
basal) in the third and fourth rounds of panning, respec-
tively.
Genomic DNA isolation and PCR amplification of insert
At the end of the fourth round, eluted phages were titered
on IPTG/X-gal plate and genomic DNA was isolated-
from randomly selected 20 colonies using DNA isola-
tion protocol (Ph.D. Phage Display Libraries kit man-
ual). The polymerase chain reaction (PCR) amplifica-
tion was done to amplify 36 nt insert by using the for-
ward primer- GCAAGCCTCAGCGACCGAAT and re-
verse primer- CCCTCATAGTTAGCGTAACG, which an-
neal ∼130 bp upstream and downstream of constant flank-
ing region of insert (total amplicon length 360 bp) by using
program in thermal cycler [95◦C initial denaturation for 5
min, 35 cycles for 95◦C denaturation 30 s, 55◦C annealing
for 30 s. and 72◦C amplification 30 s and final extension at
72◦C for 5 min using the fusion DNA polymerase enzyme].
The amplified PCR product was run on 1.5% agarose gel
and band of our interest (360 bp) was gel purified by QI-
Aquick Gel Extraction Kit. The final DNA amplicon was
quantified using nanodrop and 500ng of each sample was
sent for sequencing (RSCC Company). From sequencing
result, we identified the sequence of interest which codes
for the 12 amino acid residues peptide and translated into
amino acid sequence using online available ExPASy: SIB
Bioinformatics Resource Portal tool.
Ion torrent sequencing
For ion torrent sequencing, the genomicDNAwere isolated
using Quiagen M13 genomic DNA isolation kit (QIAprep
Spin M13 Kit) from amplified phage pool of fourth round
selection. The fusion primers (adapter sequence which was
used in sequencing and primer for amplification of insert)
were used to amplify the 170 bp length of amplicon having
36 bp insert.
Forward primer (P1)-CCTCTCTATGGGCAGTCGGT
GATTCGCAATTCCTTTAGTGGTACC,
reverse primer (A1 RP1)CCATCTCATCCCTGCGTG
TCTCCGACTCAG ATCACGTTC TGTATGGGA TT
TTGCTAAACAAC.
The fusion primers were designed in such a way that it
contains primer sequence for amplification of insert as well
as adapter sequence, which will help in sequencing. Details
about the ion torrent library preparation and design of the
fusion primer is available in ion torrent library prepara-
tion manual (Ion Amplicon Library Preparation (Fusion
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Method) Publication Number 4468326). The template was
prepared from amplified PCR using ion one touch instru-
ment and enrichment of positive ion sphere particle was
done using Ion one touch ES instrument (Ion OneTouchTM
Template Kit, 4468660). Details about the template prepa-
ration and enrichment of positive ion sphere particle is
available in template preparationmanual (IonOneTouchTM
Template Kit, Catalog Number 4468660). The prepared
template was sequenced in ion torrent sequencer using the
manual Ion Sequencing Kit User Guide v2.0, 4468997. We
wrote a program in perl for analysis of the output fastQ file
generated after sequencing, to find out the type of peptide
enriched after fourth round of panning.
Fluorescence spectroscopy
Intrinsic fluorescence spectra of the tryptophan containing
peptides were measured in Fluoromax 4 (Spex) spectroflu-
orophotometer. The excitation wavelength was set at 285
nm, and the emission spectra were recorded from 330 to 400
nm. In the titration experiments, the peptide concentration
was fixed at 100 nM in a buffer containing 10 mMTris-HCl
(pH 7.5), 10 mM NaCl, 1 mM MgCl2 and the concentra-
tions of the pre-miRNAs were varied from 0 to 2 M. The
changes in the fluorescence intensity at 355 nm (maximum
wavelength) were monitored as a function of pre-miRNA
concentrations. For data analysis,
F = F/(Fi − 1)
where F is the observed fluorescence intensity at each titrant
concentration and Fi is the fluorescence intensities of ini-
tial states of titration. The data were fitted in the following
equation:
y = P1x(P2 + x)
Peptide modeling and Docking
Conformational modeling of the peptide was carried us-
ing PEP-FOLD (39). PEP-FOLD is based on concept of
structural alphabets, which are assembled using greedy al-
gorithm. Greedy algorithm is an approximation algorithm
in which a global optimum solution is reached by making
step-by-step local optimum choices. It is called ‘greedy’ due
to its short-sighted approach of taking into account the best
local optimal solutions in solving a problem rather than
having a global overview. The models were ranked accord-
ing to their GDT score. Global distance test (GDT) is a
measure of model assessment by superimposing structural
models of the same sequence and is calculated by the av-
erage score at difference distance cutoff. It is a widely ac-
cepted standard measure used in the Critical Assessment of
protein Structure Prediction (CASP) experiments. To check
for conformational stability, molecular dynamic simulation
was done using GROMACS 4.6.1 (40). All atomistic simu-
lations were carried out using the CHARMM27 all-atom
force field (version 2.0) (41–43) using periodic boundary
condition. The starting models were solvated in a periodic
box with TIP3 water model. Na ions were added to the sol-
vent to neutralize electrical net charge of the protein. Each
system was then minimized for 50000 steps using a steep-
est decent algorithm. The NPT (the number of particles,
system pressure and temperature conserved) ensemble was
used for production simulation. Systems were simulated at
310K, maintained separately for proteins, lipids, water by
a Berendsen thermostat with a time constant of 1 ps. Pres-
sure coupling was done employing a Berendsen barostat us-
ing a 1 bar reference pressure and a time constant of 2 ps.
Electrostatic interactions were calculated using the particle
mesh Ewald (PME) summation.
The miRNA was modeled using mc-fold | mc-sym
pipeline (44). Docking between the modeled peptide and
miRNAwas performed using Zdock 3.0.2 (45). ZDock uses
a Fast Fourier Transformation (FFT) algorithm to search
the rotational space. The models were ranked according to
their ZDock score, which is based on a shape complimen-
tary scoring function.
Enzymatic footprinting
P32-5′ end labeled pre-miR-21 was subjected to a denatura-
tion and renaturation procedure before structural probing.
The P32-5′ end-labeled RNA (60000 cpm) was incubated in
10 mM Tris-HCl (pH 7.5), 10 mM NaCl, 1 mM MgCl2
in a total volume of 8 l. The sample was heated to 90◦C
for 5 min and allowed for slow cooling to 37◦C. 1 l pep-
tide was added to a final concentration of 200 nM, 500 nM
and 1 M and incubated at 37◦C for 30 minutes. 1 l of
S1 nuclease (47.5 U) (Fermentas) was added and incubated
at 37◦C for 90 s. Reaction was stopped by adding 95% for-
mamide with dyes followed by immediate snap chilling on
dry ice. Alkaline digestion ladder and RNase T1 digestion
ladder was generated as described by Regulski et al. (46).
Samples were run in 15% denaturing PAGE and exposed
to phosphor screen overnight. Images were obtained using
Typhoon FLA 7000 phosphoimager. Cleavage profiles were
generated using ImageQuant 5.2 software.
Dicer blocking assay
P32-5′ end-labeledRNA (40000 cpm,∼10 ng) was incubated
in a buffer containing 10 mM sodium cacodylate, 1 mM
MgCl2, and 10mMNaCl (pH 7.5) in a total volume of 8l.
The reactionmixture was heated at 90◦C for 5min, followed
by slow cooling to 37◦C. 1 l peptide was added to a final
concentration of 50 nM, 100 nM, 200 nM, 500 nM and 1
M, incubated for 30 min followed by addition of 1l (0.05
units) of recombinant turbo Dicer (Genlantis). For mutant
peptide, only 1 M concentration was used. The assay was
performed at 37◦C for 1 h. Reaction was stopped by adding
Dicer stop buffer (Genlantis). 10 l 95% formamide with
dyes (Xylene Cyanol and Bromophenol Blue) were added
and ran in a 15% denaturing PAGE. Gel was exposed to
phosphor screen overnight and image was taken using Ty-
phoon FLA 7000 phosphoimager.
Quantitative uptake of peptide inside the cell
Carboxyfluorescein (FAM)-conjugated peptide was added
onto MCF-7 cells with ∼80% confluence in serum free me-
dia. Cells were then incubated at 37◦C humidified incuba-
tor (5% CO2) for 6 h. Cells were washed twice with ice cold
PBS containing 1mg/ml heparin, followed by onewashwith
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trypan blue and two washes with ice cold PBS. Cells were
trypsinised, followed by centrifugation at 700 g for 5 min at
4◦C. Cell pellet was resuspended in ice cold PBS and FACS
analysis was done in BD Accuri instrument. 10000 counts
per sample was analyzed using BD Accuri C6 software.
Quantitative real time PCR for miR-21
Cells maintained in growth medium (DMEM high-glucose,
10% FBS, without antibiotic and antimycotic) were pas-
saged in 24-well plate (5 × 104 cells/well), grown to 80%
confluency and treated with different concentrations of the
peptides. Cells were then incubated at 37◦Chumidified incu-
bator (5% CO2) for 24 h. Total RNAwas isolated from cells
using TRizol R© Reagent (Invitrogen). Expressions of ma-
ture microRNAs were determined by QuantiMir kit. (SBI,
catalog number RA660A-1). Primers used for qRT-PCR is
listed below:
Forward primer: TAGCTTATCAGACTGATGTTGA
Reverse primer: QuantiMir universal reverse primer
The microRNA expression levels were detected using
SYBR-green I PCR master mix (Applied biosystems) on
Roche Lightcycler LC 480 and normalized with respect to
U1 as a reference gene. The Real Time data analysis was
done by using 2(-Delta Delta C(T)) method (47).
miRNA expression profiling
MCF-7 cells were cultured in 6-well plate (3 ×
105cells/well), grown to 80% confluency and treated
with peptide in a final concentration of 1 M. 24 h post
treatment, total RNA was isolated using TRizol R©Reagent
(Invitrogen, USA). 1 g of starting RNA was used to syn-
thesize cDNA. Universal Reverse primer was provided by
Human miRNome profiler kit (SBI). MiRNA expression
profiling was done in pre-formatted qPCR array format as
provided by System Biosciences (SBI).
Western blot
Total protein was isolated from treated and untreated
MCF-7 cells using cell lysis RIPA buffer (Pierce Chemi-
cal Co., Rockland, IL). Four LNA modified anti-miR-21
(100 nM) (Anti-miR-21 sequence: TCAACATCAGTCTG
ATAAGCTA (residues underlined are LNA modified))
transfected sample was also taken as positive control. Pro-
tein concentration was estimated using BCATM protein as-
say (Pierce Chemical Co., Rockland, IL). An equivalent
amount of protein from each treatment was resolved on
12% SDS-PAGE. Following transfer to nitrocellulose mem-
brane and blocking with 5% non-fat milk, the blot was incu-
bated with primary antibody (1:1000) specific for PDCD4
protein and PTEN(abcam). After washing the blot with 1X
TBST, it was probed with alkaline phosphatase conjugated
secondary antibody (1:10000 dilutions)(abcam). The blot
was developed using AP developing solution (Sigma) fol-
lowed by densitometric analysis (ImageJ software, NIH).
Detection of proliferation using Immunofluorescence
Cells were seeded on square coverslips in six-well plates
and treated with peptide and mutant at 1 M for 48 h.
Subsequently, cells were fixed with 2% paraformaldehyde
for 20 min at room temperature. For permealization, 0.5%
Triton X-100 prepared in phosphate-buffered saline (PBS)
was applied for 15 min at room temperature, followed by
three washes with PBS for 5 min each. Nonspecific bind-
ing was blocked by incubation with 5% bovine serum al-
bumin (BSA) in PBS for 30 min at room temperature.
The cells were treated with primary anti-Ki67 antibody
(1:1000, Abcam) and incubated overnight at 4◦C. To visual-
ize Ki67, cells were incubated with Alexa Fluor 488-labeled
secondary antibody (1:250 dilutions, Invitrogen) for 45 min
at room temperature. All antibodies and staining reagents
were diluted in 5% BSA-PBS. Coverslips were mounted
with ProLongGold antifade reagent with DAPI (Life Tech-
nologies). Images were taken using a Zeiss LSM 510 Meta
confocal microscope at 63X.
Apoptosis detection by TUNEL assay
MCF-7 cells were seeded on poly-lysine coated coverslips
in 6-well plates (3× 105 cells/well) and treated with peptide
and mutant at a final concentration of 1 M and grown for
48 h. Next, the cells were washed twice with 1X PBS, and
fixed in 4% paraformaldehyde for 20 min at room temper-
ature. The fixed cells were permeabilized with 0.2% Triton
X-100 for 5 min at room temperature, followed by washing
with 1X PBS. To determine the effect of peptide treatment
on apoptosis, we performed the apoptosis assay using the
DeadEndTM Colorimetric TUNEL System kit (Promega)
following the instructions of the manufacturer. Briefly, the
cells were incubated with TUNEL reaction mixture (bi-
otinylated nucleotide mix) for 60 min at 37◦C in a hu-
midified chamber. Negative control was prepared and was
treated with the TUNEL label reaction mixture (without
Terminal deoxynucleotidyl transferase enzyme). Endoge-
nous peroxidase activity was quenched using 0.3% H2O2
for 5 min at room temperature. The cells were treated with
streptavidin-HRP (1:500) and stained with DAB compo-
nents. The cells were washed with de-ionized water several
times before imaging.
Invasion and migration assay
Cancer cell invasion and migration assay was done using
CytoSelect cell migration and Invasion assay kit (Cell Bio-
labs, Inc.) using manufacturer’s protocol. Briefly, 24 h after
treatment, cells were counted and placed on control inserts
orMatrigel inserts at 105 cells/ml in serum-freemediumand
were allowed tomigrate for 24 h at 37◦C.Cells were removed
from the top of the inserts and cells that migrated/invaded
though the polycarbonate basement membrane were fixed,
stained and imageswere taken in lightmicroscope.Next, the
stained basement membrane was extracted and quantified
at optical density of 560 nm.
Cell viability assay
MCF-7 cells were seeded in 96 well-plates (8000 cells/well),
grown to 80% confluency and then treated with peptides
at different concentrations ranging from 0 to 1 M. Af-
ter 24 and 48 h of growth, cells were treated with 1 mg/ml
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3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bro-
mide (Sigma-Aldrich) and incubated for 4 h at 37◦C in CO2
incubator. After incubation, the medium was removed and
formazan crystals were dissolved in 200l DMSO solution.
Sample absorbance was measured at 570 nm with a refer-
ence wavelength of 630 nm. Data were normalized with un-
treated control set.
RESULTS
Phage display against pre-miR-21
To find out selective peptides against pre-miR-21, we
have used phage display. A schematic presentation of the
workflow has been summarized in supporting information
Scheme S1.
Pre-miR-21 was in vitro transcribed followed by biotiny-
lation at the 3′ end. Solution phage panning was carried
out with streptavidin coated magnetic beads. After do-
ing negative selection against streptavidin and tubes, four
rounds of panning were carried out with increasing strin-
gency. To achieve selectivity against pre-miR-21, non bi-
otinylated pre-miR-27a (for the first two rounds of panning)
and HEK293T total cellular RNA, where miR-21 expres-
sion is reported to be very low (48,49), (for the last two
rounds of panning) were pre-incubated to the phage pool,
followed by panning against pre-miR-21. Deep sequenc-
ing of the amplified library was done after fourth round of
panning. Out of 12261 reads, 9513 reads correspond to a
common peptide motif ‘ALWPPNLHAWVP’ and the oth-
ers were found be the same motif with one or two amino
acid substitutions. Traditional colony based sequencing was
also carried out. 20 colonies against pre-miR-21 were se-
quenced after fourth panning and all of them gave the same
motif of ‘ALWPPNLHAWVP’. This indicated that ALW-
PPNLHAWVP peptide can be the potential binder of pre-
miR-21.
In vitro binding to pre-miR-21
Next we wanted to explore the binding interaction between
the ALWPPNLHAWVP peptide and pre-miR-21. Along
this line we have taken two control peptides: (i) reverse mu-
tant: PVWAHLNPPWLA and (ii) scrambled mutant: LP-
PAPWNWAHVL. All the peptides have the same amino
acid composition, while the sequences are different and
hence will allow us to examine sequence specific interaction.
All the peptides contain two tryptophan residues; allowing
us to look for intrinsic fluorescence change in the presence
of pre-miR-21. In the presence of pre-miR-21, we found a
decrease in fluorescence for thewild-type peptide, indicating
strong interaction. Themutant peptides did not show signif-
icant change. Quantitative analysis of fluorescence titration
(binding isotherm) showed strong binding of pre-miR-21 to
wild-type peptide with dissociation constant 12.7 nM, while
the mutants showed weak binding (Figure 1). This clearly
indicated that the selected peptide binds to pre-miR-21 in a
sequence-specific manner.
Figure 1. Binding analysis of peptide with pre-miR-21. Binding isotherm
of wild-type peptide (red), reverse mutant (blue) and scrambled mutant
(green) with pre-miR-21.
Identification of the binding pocket of peptide to pre-miR-21
Provided the strong binding of the peptide to pre-miR-21 it
was interesting to look for the binding pocket in pre-miR-
21.
An in-silico approach was used to predict and study the
binding pose of the peptide to the miRNA. The first step
involved the prediction of the secondary and tertiary struc-
ture of the pre-miR using mc-fold mc-sym pipeline. The
energy-minimized model was obtained using the method’s
scoring function, which calculates the base pairing energy
contribution by reducing the nucleotides into cyclic motifs.
PEP-FOLD web server was used for the peptide structure
prediction. PEP-FOLDpredicts structure based on concept
of structural alphabets. The best peptide model with the
highest GDT score (0.732) was chosen for an all atomistic
molecular dynamic simulation to check for conformational
stability using GROMACS 4.6.1. A simulation of 100 ns
revealed that the central residues were found to markedly
more stable than the flanking region. Also the structure of
the model remained stable post 20 ns (Supplementary Fig-
ure S1). This stabilized structure of the peptide was then
used along with themodeled pre-miR for the docking study.
For docking, we used ZDock, an FFT algorithm, which
searches the rotational space to give a shape complimentary
score. The method gave an ensemble of 99 models (Supple-
mentary Figure S2), which were ranked to the above men-
tioned ZDock score. To further critically assess the predic-
tion; the top 20 models were then manually studied to eval-
uate them based on the interactions between the peptide
and pre-miR-21. The best model was chosen from this list;
which had a high ZDock score (1267.761) as well as high
intra-model residue contacts (Figure 2). The model chosen
had interactions between residues (1–6, 10, 12) of the pep-
tide and residues (43–46 and 35–32) of the pre-miRNA.
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Figure 2. Manually picked model (Rank 4) having ZDock Score of
1267.761. (A) Docked model of peptide (coloured in green) bound to the
pre-miR-21 (B) Magnified view of the docked structure showing the sol-
vent accessible surface area (SASA) and contacts (coloured in purple) be-
tween the peptide and pre-miR-21. The SASA and contacts were calcu-
lated using Chimera.
Figure 3. S1 nuclease probing of pre-miR-21 and peptide interaction.
(A) Cleavage pattern of uncomplexed pre-miR-21(lane 3) and pre-miR-21
complexed with increasing concentrations of peptide (lanes 4 to 6). Lanes
1 and 2 represent the T1 digestion ladder and alkaline hydrolysis ladder,
respectively. (B) Representative plot of the intensity of bands from nu-
cleotides 31–45 for uncomplexed premiR-21 (black line), pre-miR-21 com-
plexed with 200 nM, 500 nM and 1 M peptide (red, green and blue line).
(C) The sites of protection mapped to the pre-miR-21 structure(colored in
blue, numbered in red).
To validate the in-silico result further, we did enzymatic
footprinting of pre-miR-21 in the presence of increasing
concentration of the peptide (0–1 M). S1 nuclease foot-
printing was done to figure out the binding pocket. S1 nu-
clease cleaves single stranded and unconstrained nucleic
acid endonucleolytically. A closer inspection indicated that
residues 33–45 showed protection in S1 nuclease footprint-
ing (Figure 3 and Supplementary Figure S3). This reduced
cleavage in the presence of increasing concentrations of pep-
tide indicated the binding pocket lies near the stem-loop
junction of pre-miR-21 (Figure 3).
Exploring inhibitory role of the peptide
Given that the peptide binding pocket is near the stem loop
junction, a portion where Dicer cleaves to form mature
miRNA, it was interesting to ask whether the peptide bind-
ing can hinder Dicer processing and thus inhibit mature
miRNA formation. To this end, we did Dicer cleavage assay
in the presence of increasing concentration of the peptide. A
significant decrease in mature miR-21 level was found in the
presence of increasing concentration of peptide (0–1 M),
while the mutant peptides were unable to show any signif-
icant change in mature miR-21 formation (Figure 4). This
clearly indicates that the peptide can inhibit mature miR-21
formation in vitro by binding to the stem-loop junction of
pre-miR-21 and thereby blocking Dicer processing.
Probing the importance of single nucleotide bulges near the
terminal loop of pre-miR-21; in peptide binding and hence in-
hibitory function
We wanted to probe the importance of the bulges near the
terminal loop (as revealed by enzymatic probing) in the
binding interaction of peptide and pre-miR-21. To this end,
we used a mutant pre-miR-21 where the bulge is absent
(Supplementary Figure S4). Fluorescence titration study
showed very weak binding of the peptide to this mutant
pre-miR-21 (Supplementary Figure S5). In-vitro enzymatic
footprinting did not show any protection as previously ob-
served in the presence of peptide (Supplementary Figure
S6). Dicer blocking assay did not show any effect in miR-21
maturation in the presence of peptide (Supplementary Fig-
ure S7). Collectively the evidence suggests that the bulges
are important structural determinants for peptide binding
and hence inhibition of Dicer processing. We have also
checked the binding of the peptide to two other struc-
turally different oncogenic pre-miRNAs (pre-miR-95 and
pre-miR-103) and did not find any significant binding in-
teraction (Supplementary Figure S5). This suggested selec-
tivity of the peptide to pre-miR-21.
Assessing miR-21 inhibitory efficiency inside the cell
As the peptide contains three proline residues, we reasoned
that the peptide may have cell penetrating properties. To
check the cell penetrating property, we FAM conjugated
the peptides and monitored their uptake by flow cytometry.
Flow cytometry analysis clearly indicated cell penetrating
potential of the wild-type peptide, as well as the scrambled
and reverset peptides (Supplementary Figure S8).
To evaluate the efficacy of the peptide inhibitor inside
cell, we checked mature miR-21 expression using qRT-PCR
inMCF-7 cells (where endogenousmiR-21 is reported to be
over expressed). A dose dependent (0–10 M) inhibition of
miR-21 level was found after 24 h of treatment with satura-
tion at 1 M of peptide, confirming its inhibitory potential
inside the cell. The scrambled and reverse peptides were to-
tally ineffective in down regulating miR-21 (Figure 5A).
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Figure 4. Dicer blocking assay. (A) Dicer blocking assay with wild-type peptide (lane 1: pre-miR-21 with Dicer, lanes 2 to 6: pre-miR-21 with Dicer in
the presence of increasing concentrations of peptide). (B) Densitometric analysis of miRNA levels for the mentioned above assays showing a decrease in
miR-21 formation with increasing concentration of peptide. (C) Dicer blocking assay in the presence of the two mutant peptides did not show any effect
in miR-21 maturation. Error bars represent ±SD, calculated from three independent experiments.*, P < 0.01 (Student’s t-test).
Figure 5. Inhibitory potential inside cell. (A) Relative levels of mature miR-21 shown at increasing concentrations of wild-type (black) andmutant peptides
(green and blue) treatment (200 nM to 10 M). (B) miRnome wide change in miRNA expression level (log2 fold change) upon 1 M peptide treatment.
(C) Western blot detection of PDCD4 and PTEN shows increased levels upon peptide treatment, while mutants were ineffective. Anti-miR-21 (100 nM)
was taken as positive control. (D) Relative fold-change analysis (black bar for PDCD4 and gray bar for PTEN). Error bars represent±SD, calculated from
three independent experiments.*, P < 0.01 (Student’s t-test).
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Figure 6. Impact of peptide on cell proliferation and apoptosis. (A) Peptide treated cells revealed lower level of Ki-67 marker, indicating inhibition of cell
proliferation. The mutants were ineffective. (B) Peptide treated cells revealed increased number of tunel positive apoptotic cells (∼30%), while the mutants
did not show significant effect. Error bars represent ±SD*, P < 0.01 (Student’s t-test).
To check the selectivity of the peptide against miR-21 in-
side the cell, qRT-PCR based miRNome profiling was done
in MCF-7 cells using SBI miRNome miRNA profiler. In
MCF-7 significant expression level of 762 miRNAs were
detected. After 24 h of treatment of 1 M peptide, 13 miR-
NAs were found to be down regulated and 20 miRNAs to
be upregulated (2-fold expression changes was the cut-off).
Literature survey indicated that out of those 33 miRNAs,
24 miRNAs were discovered via high throughput sequenc-
ing studies and are not functionally annotated. With the
rapid advancement of the sequencing technology, numer-
ous novel miRNAs are being constantly deposited in the
miRBase database, but many of them are turning out to be
not bona fidemiRNAs and are by product of annotation as-
signment error (50,51). Thus, we removed those 24 low con-
fidence miRNAs and out of the resultant 9 miRNAs, 6 were
down-regulated and 2 were up-regulated (Figure 5B). Both
miR-21 and miR-21* was found to be significantly down-
regulated in this miRNome profile also. This result clearly
indicates that the peptide is very selective toward miR-21.
Next, we wanted to assess the impact of the peptide on
miR-21 functional targets, on whether it can antagonize
miR-21 function. We checked the expression level of two
miR-21 targets, PDCD4 and PTEN. In the presence of in-
creasing concentration of peptide (0–1 M), we found in-
crease in both PDCD4 and PTEN in MCF-7. The two mu-
tants were not effective (Figure 5C andD).We also checked
the expression of PDCD4 in the presence of peptide (1
M) in HEK293T cell line where the miR-21 expression
is low (48,49) and we did not find any significant change
compared to the untreated control (Supplementary Figure
S9A). Along the same line, we over-expressed wild-type pre-
miR-21 and mutant pre-miR-21 in HEK293T cell line and
then checked the effect of the peptide. Over-expression of
either of the two pre-miR-21 reduced the level of PDCD4
compared to the control, as in the both the cases mature
miR-21 was formed. Peptide was able to restore the level of
PDCD4 back to the control, but was ineffective in case of
mutant pre-miR-21, due to its inability to bind to mutant
pre-miR-21 (Supplementary Figure S9B and S9C). Taken
together, the peptide inhibits miR-21 formation and thereby
up-regulates its target proteins.
Effect of peptide on cancer cell proliferation and apoptosis
Proliferation is a hallmark of tumorigenesis. PDCD4, one
of the important targets of miR-21, regulate translation by
directly interacting with translation initiation factor eIF4A
and blocking eIF4G helicase activity and thereby causes de-
crease in protein synthesis, inhibition of proliferation and
increase in apoptosis (52–54). Thus, silencing of miR-21
suppresses tumor cell proliferation and increases apopto-
sis. We went on to check the potential of miR-21 inhibitor
peptide to modulate cell proliferation and apoptosis. Im-
munostainingwith anti-Ki-67 cells showed fewerKi-67 pos-
itive cells in peptide treated condition, compared to the un-
treated control (Figure 6A) while the mutants did not show
the effect. We did TUNEL assay to check for apoptosis in-
duced by the peptide and found that there was around 30%
increase of apoptosis in the presence of the peptide inhibitor
(Figure 6B). Along the same line, we didMTT assay to look
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Figure 7. Impact of peptide on MCF-7 cell invasion and migration. (A) Peptide treated cells revealed reduced cell invasion and migration, while mutants
were ineffective. (B) Quantitative analysis showed ∼50% reduction in cell invasion (black bar) and ∼30% reduction cell migration (gray bar) upon peptide
treatment. Error bars represent ±SD, calculated from three independent experiments.*, P < 0.01 (Student’s t-test).
for cell viability in the presence of different concentrations
(0–1M)of peptide. Around 20% cell deathwas found after
48 h of treatment, which is probably due to increased apop-
tosis (Supplementary Figure S10). There was no significant
change in cell viability after 24 h of treatment (Supplemen-
tary Figure S10). We also checked the effect of the peptide
on cellular apoptosis in HEK293T cell line where miR-21
expression is low (48,49) and no significant increase in apop-
tosis was found compared to untreated control (Supplemen-
tary Figure S11). Taken together, our data indicate that the
peptide is potent to suppress tumor cell proliferation and
survival via miR-21 downregulation.
Effect of peptide on cell invasion and migration
Tumor cell invasion and migration are crucial steps of
metastasis and miR-21 helps in cell migration and inva-
sion in different kinds of cancer (including breast cancer)
by targeting tumor suppressors PDCD4, PTEN, TMP1 and
maspin (55). Down-regulation of miR-21 was shown to in-
hibit cell migration and invasion both in cell and in vivo
(36,55). To assess the impact of the peptide inhibitor on
cell migration, we performed scratch wound assay. In this
assay a linear scratch was made in the cell layer and cell’s
ability to heal the scratch (because of its migration poten-
tial) was assessed. The peptide was found to be a potent in-
hibitor of MCF-7 migration (Supplementary Figure S12).
We also wanted to check the effect of this peptide in a more
metastatic cell line MDMB231, where miR-21 is also over-
expressed. We checked the endogenous level of miR-21 in
MDMB231 cell line in the presence of peptide (1 M) and
found down-regulation of miR-21 upon peptide treatment
(Supplementary Figure S13). Scratch assay in MDMB231
showed similar results (Supplementary Figure S12).We also
did transwell assay to monitor cell invasion and migra-
tion. As shown in Figure 7 and Supplementary Figure S14,
we found a significant decrease in cell invasion and migra-
tion (both in MCF-7 and MDMB231 cell lines) in peptide
treated group compared to untreated control, while the mu-
tant was ineffective. The peptide was ineffective in reduc-
ing cell invasion and migration in low miR-21 condition,
HEK293T cell line (Supplementary Figure S15). These re-
sults clearly indicate that the peptide is capable of inhibiting
cancer cell invasion andmigration by antagonizingmiR-21.
DISCUSSION
Distinct groups of miRNAs are reported to be up-regulated
or down-regulated in different types of cancer and are as-
sociated with disease progression and maintenance. As a
single miRNA controls multiple genes, miRNAmodulation
based therapeutics is emerging to be a potential new avenue
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to target multiple gene interaction networks and thereby
target cancer with more efficacies. Given the drawbacks of
oligonucleotide based therapeutics, recent efforts have been
put forward to look for alternate strategies for modulation
of miRNA. Different groups, including us, have reported
small molecule inhibitors against miRNA. Though these
small molecules were shown to have some selectivity against
a particular miRNA, none of them were tested for their off-
target effect in miRNome expression. With the recent im-
provement in peptide based therapeutics, because of its bet-
ter specificity and hence less off target effect, it is worth to
explore peptide based specific modulator of miRNA. Diaz
et al. have previously shown the potential of peptoid to
down regulate miR-21 in vitro (22).
In our study, using phage display we have identified a spe-
cific peptide against oncogenic miR-21. It inhibits mature
miR-21 formation by binding to pre-miR-21 and thereby
Dicer processing. The peptide is also effective in down reg-
ulating miR-21 in cells and hence antagonizing its function.
It is specific to miR-21 inside the cell. The peptide was ef-
fective in inhibiting cancer cell invasion, migration and pro-
liferation and activating apoptosis by modulating miR-21
targets, including PTEN and PDCD4. Taken together, this
peptide and its peptidomimetic derivatives can be explored
for its potential anti cancer activity in vivo and may further
be extended to clinical studies.
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